Introduction. Long-acting subcutaneous testosterone pellets provide sustained and steady testosterone levels for 3to 6 months. Testopel® subcutaneous crystalline testosterone pellets are U.S.-approved for the treatment of men withtestosterone deficiency syndrome. Published experience with testosterone pellets manufactured by Organon hasnoted relatively high rates of pellet extrusion and infection.

Aim. To report safety and limited efficacy data from our patients treated for testosterone deficiency syndrome withTestopel® subcutaneous testosterone pellets.

Main Outcome Measures. Infection with or without pellet extrusion, as determined by longitudinal follow-up.

Methods. Single-site, retrospective analysis of medical records from December 2003 through April 2008.

Results. A total of 80 men met inclusion and exclusion criteria. In the 292 implant procedures performed, fouradverse events were reported including one implantation site infection. No spontaneous pellet extrusions werereported. Total and free testosterone concentrations were significantly higher at follow-up than at baseline for allpatients. Eighty-six percent of patients were satisfied with this treatment modality based on symptom improvementor having subsequent implant procedures.

Conclusions. Testosterone replacement with long-acting Testopel pellets had a lower rate of infection (0.3%, 1/292procedures) as compared with historical data from the Organon testosterone pellet (1.4–6.8%). Additionally, the rateof pellet extrusion was substantially lower (0.3%, 1/292 procedures) as compared with historical data (8.5–12%).None of the patients who complied with post-implant procedure instructions experienced infection or pelletextrusion. Patient satisfaction was high and serum hormone values were improved. The low infection and extrusionrates observed may have been the result of the manufacturing process, which results in small, smooth-surfacedpellets; the absence of foreign material within the pellet packaging; and/or differences in the surgical implantationtechnique used. Though Testopel pellets have been used in the United States for several decades, more research isneeded to document their safety and efficacy.

Cavender RK, and Fairall M. Subcutaneous testosterone pelletimplant (Testopel®) therapy for men with testosterone deficiency syndrome: A single-site retrospectivesafety analysis. J Sex Med 2009;6:3177–3192.